rs201692618
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_152594.3(SPRED1):c.30C>A(p.Asn10Lys) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.000344 in 1,576,894 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_152594.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPRED1 | ENST00000299084.9 | c.30C>A | p.Asn10Lys | missense_variant, splice_region_variant | 1/7 | 1 | NM_152594.3 | ENSP00000299084.4 | ||
SPRED1 | ENST00000561317.1 | c.-98C>A | splice_region_variant | 1/6 | 4 | ENSP00000453680.1 | ||||
SPRED1 | ENST00000561317 | c.-98C>A | 5_prime_UTR_variant | 1/6 | 4 | ENSP00000453680.1 | ||||
SPRED1 | ENST00000561205.1 | n.368C>A | splice_region_variant, non_coding_transcript_exon_variant | 1/5 | 5 |
Frequencies
GnomAD3 genomes AF: 0.000421 AC: 64AN: 152172Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000625 AC: 120AN: 192104Hom.: 0 AF XY: 0.000636 AC XY: 65AN XY: 102254
GnomAD4 exome AF: 0.000336 AC: 479AN: 1424604Hom.: 1 Cov.: 31 AF XY: 0.000343 AC XY: 242AN XY: 704970
GnomAD4 genome AF: 0.000420 AC: 64AN: 152290Hom.: 0 Cov.: 31 AF XY: 0.000322 AC XY: 24AN XY: 74466
ClinVar
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 05, 2020 | This variant is associated with the following publications: (PMID: 31401120, 26635368, 22753041) - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Legius syndrome Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2025 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 17, 2023 | Variant summary: SPRED1 c.30C>A (p.Asn10Lys) results in a non-conservative amino acid change located in the WH1/EVH1 domain (IPR000697) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00062 in 192104 control chromosomes. The observed variant frequency is approximately 111 fold of the estimated maximal expected allele frequency for a pathogenic variant in SPRED1 causing Neurofibromatosis Type 1-Like Syndrome (Legius Syndrome) phenotype (5.6e-06), strongly suggesting that the variant is benign. c.30C>A has been reported in the literature in individuals with varying phenotypes including Noonan Syndrome-associated characteristics and Neurofibromatosis Type 1-Like Syndrome (Legius Syndrome) (e.g. Brems_2012, Bhoj_2017, Delio_2015, Hirata_2016). These reports do not provide unequivocal conclusions about association of the variant with Neurofibromatosis Type 1-Like Syndrome (Legius Syndrome). Functional assessment of the variant determined that it does not disrupt the interaction between the SPRED1 EVH1 domain and the NF1 GAP-related domain and that its ERK suppression activity is similar to the wild-type (Hirata_2016). The following publications have been ascertained in the context of this evaluation (PMID: 27763634, 22753041, 26214305, 26635368). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign. - |
SPRED1-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 27, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 28, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Noonan syndrome and Noonan-related syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | May 27, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at